Lianhuan Pharma Gets Good Manufacturing Practice Certificates for Three Products

MT NewswiresDec 24, 2024 15:21

Jiangsu Lianhuan Pharmaceutical (600513.SH): received the Pharmaceutical GMP compliance inspection results.

On December 23, according to Gelonghui, Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that it received the "Drug GMP Compliance Inspection Result Notification" from the Jiangsu Provincial Drug Administration website. The scope of inspection includes: Active Pharmaceutical Ingredient [sacubitril/valsartan sodium, Workshop 2, C7-H1 production line (hydrogenation), C5-H1 production line (esterification), C5-H2 production line (acylation), No. 8 fine package (co-crystal)]; Oral solution [Workshop 3, Production line 2 (oral solution)]; Tablets [antitumor drugs, Workshop 3, Tablet (antitumor) production line]. According to the "Drug Administration Law" and "Drug Production Supervision Management"

Gelonghui FinanceDec 23, 2024 16:52

Express News | Jiangsu Lianhuan Pharmaceutical: Increased investment in Yangzhou Lianhuan by 50 million yuan.

BreakingsDec 19, 2024 18:01

China Approves Jiangsu Lianhuan Pharmaceutical's Heart Failure Treatment Injection

MT NewswiresDec 3, 2024 15:49

Express News | jiangsu lianhuan pharmaceutical: has obtained the pharmaceutical registration certificate for digoxin injection.

BreakingsDec 2, 2024 16:49

Express News | The trial production line of active pharmaceutical ingredients at jiangsu lianhuan pharmaceutical has successfully passed the trial run.

BreakingsNov 22, 2024 14:50